Tau-targeting therapy in Alzheimer’s disease: critical advances and future opportunities

Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172

Alzheimer's disease

Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616

Alzheimer disease

Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606

2022 Alzheimer's disease facts and figures

Anonymous (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12638 · Cited by 2,469

Staging of alzheimer's disease-related neurofibrillary changes

Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.

Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,142

The role of autophagy in neurodegenerative disease

Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049

Transmission and spreading of tauopathy in transgenic mouse brain

Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803

Engineering exosomes for targeted drug delivery

Liang, Y., Duan, L., Lu, J., & Xia, J. (2021) · Theranostics · doi:10.7150/thno.52570 · Cited by 1,547

Alzheimer’s Disease Neuroimaging Initiative

Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Toga, A. W., & Beckett, L. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,493

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329

Synergy between amyloid-β and tau in Alzheimer’s disease

Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242

Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy

Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease

Kametani, F., & Hasegawa, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00025 · Cited by 836

Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease

Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630428100 · Cited by 831

Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments

Alonso, A. D. C., Zaidi, T., Novak, M., Grundke-Iqbal, I., & Iqbal, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121119298 · Cited by 827

Tau and neurodegenerative disease: the story so far

Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806

Liquid–liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau

Ambadipudi, S., Biernat, J., Riedel, D., Mandelkow, E., & Zweckstetter, M. (2017) · Nature Communications · doi:10.1038/s41467-017-00480-0 · Cited by 782

Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.

Köpke, E., Tung, Y. C., Shaikh, S., Alonso, A. C., Iqbal, K., & Grundke-Iqbal, I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80536-5 · Cited by 779

O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease

Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775

Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04391.x · Cited by 759

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734

Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies

Šimić, G., Leko, M. B., Wray, S., Harrington, C. R., Delalle, I., Milošević, N. J., Bažadona, D., Buée, L., de Silva, R., Giovanni, G. D., et al. (2016) · Biomolecules · doi:10.3390/biom6010006 · Cited by 730

The acetylation of tau inhibits its function and promotes pathological tau aggregation

Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724

The β-Secretase BACE1 in Alzheimer’s Disease

Hampel, H., Vassar, R., De Strooper, B., Hardy, J., Willem, M., Singh, N., Zhou, J., Yan, R., Vanmechelen, E., De Vos, A., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.001 · Cited by 694

The release and trans-synaptic transmission of Tau via exosomes

Wang, Y., Balaji, V., Kaniyappan, S., Krüger, L., Irsen, S., Tepper, K., Chandupatla, R., Maetzler, W., Schneider, A., Mandelkow, E., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0143-y · Cited by 674

Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects

Barbier, P., Zejneli, O., Martinho, M., Lasorsa, A., Belle, V., Smet‐Nocca, C., Tsvetkov, P. O., Devred, F., & Landrieu, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00204 · Cited by 655

From Promiscuity to Precision: Protein Phosphatases Get a Makeover

Virshup, D. M., & Shenolikar, S. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.015 · Cited by 643

Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET

La Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612

Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation

Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., & Vocadlo, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.797 · Cited by 611

Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles

Cruz, J. C., Tseng, H.-C., Goldman, J. A., Shih, H., & Tsai, L.-H. (2003) · Neuron · doi:10.1016/s0896-6273(03)00627-5 · Cited by 609

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574

Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration

Wang, J., Grundke, I., & Iqbal, K. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05226.x · Cited by 569

Trans-cellular Propagation of Tau Aggregation by Fibrillar Species

Kfoury, N., Holmes, B. B., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.346072 · Cited by 552

Safety of Nanoparticles in Medicine

Wolfram, J., Zhu, M., Yang, Y. P., Shen, J., Gentile, E., Paolino, D., Fresta, M., Nie, G., Chen, C., Shen, H., et al. (2015) · Current Drug Targets · doi:10.2174/1389450115666140804124808 · Cited by 550

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547

Glycogen synthase kinase-3 signaling in Alzheimer’s disease

Lauretti, E., Dincer, O., & Praticò, D. (2020) · Biochimica et biophysica acta. Molecular cell research · doi:10.1016/j.bbamcr.2020.118664 · Cited by 543

A Phase II Trial of Tideglusib in Alzheimer's Disease

Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536

Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice

Dawson, H. N., Ferreira, A., Eyster, M. V., Ghoshal, N., Binder, L. I., & Vitek, M. P. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.6.1179 · Cited by 527

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3951 · Cited by 516

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516

The importance of tau phosphorylation for neurodegenerative diseases

Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475

Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease.

Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., Huang, D. Y., Pericak-Vance, M., Schmechel, D., & Roses, A. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11183 · Cited by 474

Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model

Shi, Y., Manis, M., Long, J., Wang, K., Sullivan, P. M., Remolina Serrano, J., Hoyle, R., & Holtzman, D. M. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190980 · Cited by 448

Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy

Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.-H., Yao, Y., Lin, Y.-M., Driver, J. A., Sun, Y., et al. (2015) · Nature · doi:10.1038/nature14658 · Cited by 445

Post-translational modifications of tau protein in Alzheimer’s disease

Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.080044 · Cited by 411

Tau aggregation is driven by a transition from random coil to beta sheet structure

von Bergen�, M., Barghorn, S., Biernat, J., Mandelkow, E., & Mandelkow�, E. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.010 · Cited by 389

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368

Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation

Alquezar, C., Arya, S., & Kao, A. W. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.595532 · Cited by 367

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

Chai, X., Wu, S., Murray, T. K., Kinley, R. D., Cella, C. V., Sims, H., Buckner, N., Hanmer, J. M., Davies, P., O’Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 363

Glycosylation of microtubule–associated protein tau: An abnormal posttranslational modification in Alzheimer's disease

Wang, J.-Z., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0896-871 · Cited by 360

Preparation and Characterization of Neurotoxic Tau Oligomers

Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Jackson, G. R., & Kayed, R. (2010) · Biochemistry · doi:10.1021/bi1016233 · Cited by 359

Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system

Lee, M. J., Lee, J. H., & Rubinsztein, D. C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.03.001 · Cited by 336

Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia

Wang, C., Xiong, M., Gratuze, M., Bao, X., Shi, Y., Andhey, P. S., Manis, M., Schroeder, C., Yin, Z., Madore, C., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.03.024 · Cited by 334

Sequential phosphorylation of Tau by glycogen synthase kinase‐3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer‐specific epitope of antibody AT100 and requires a paired‐helical‐filament‐like conformation

Zheng‐Fischhöfer, Q., Biernat, J., Mandelkow, E., Illenberger, S., Godemann, R., & Mandelkow�, E. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2520542.x · Cited by 322

Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy

Brunden, K. R., Zhang, B., Carroll, J., Yao, Y., Potuzak, J. S., Hogan, A.-M. L., Iba, M., James, M. J., Xie, S. X., Ballatore, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3059-10.2010 · Cited by 320

Antisense Reduction of Tau in Adult Mice Protects against Seizures

DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-13.2013 · Cited by 311

Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Novák, P., Schmidt, R., Kontseková, E., Žilka, N., Kováčech, B., Škrabana, R., Kazmerova, Z., Katina, S., Fialová, Ľ., Prčina, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 306

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.

Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305

Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice

Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300

AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathies

Vingtdeux, V., Davies, P., Dickson, D. W., & Marambaud, P. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0759-x · Cited by 297

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer’s disease models

van Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284

The Microtubule-severing Proteins Spastin and Katanin Participate Differently in the Formation of Axonal Branches

Yu, W., Qiang, L., Solowska, J. M., Karabay, A., Korulu, Ş., & Baas, P. W. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-09-0878 · Cited by 283

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278

Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment

Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270

Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269

Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains

Boluda, S., Iba, M., Zhang, B., Raible, K. M., Lee, V. M. ‐., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1373-0 · Cited by 268

The Emerging Link between O-GlcNAc and Alzheimer Disease

Zhu, Y., Shan, X., Yuzwa, S. A., & Vocadlo, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.601351 · Cited by 267

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 266

A review of nanoparticle functionality and toxicity on the central nervous system

Yang, Z. R., Liu, Z. W., Allaker, R. P., Reip, P. W., OXFORD, J. S., Ahmad, Z., & Ren, G. (2010) · Journal of The Royal Society Interface · doi:10.1098/rsif.2010.0158.focus · Cited by 265

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259

Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review

Gibbons, G. S., Lee, V. M. Y., & Trojanowski, J. Q. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2505 · Cited by 257

A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions

Violet, M., Delattre, L., Tardivel, M., Sultan, A., Chauderlier, A., Caillierez, R., Talahari, S., Nesslany, F., Lefebvre, B., Bonnefoy, E., et al. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00084 · Cited by 251

Tau immunotherapy for Alzheimer's disease

Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247

Lithium and suicide in mood disorders: Updated meta‐review of the scientific literature

Smith, K. A., & Cipriani, A. (2017) · Bipolar Disorders · doi:10.1111/bdi.12543 · Cited by 247

Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease

Zhang, K., Chen, M., Du, Z.-Y., Zheng, X., Li, D., & Zhou, R. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.230303 · Cited by 243

Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody

Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., & Paul, S. M. (2015) · Scientific Reports · doi:10.1038/srep11161 · Cited by 241

Brain delivery of quercetin-loaded exosomes improved cognitive function in AD mice by inhibiting phosphorylated tau-mediated neurofibrillary tangles

Qi, Y., Guo, L., Jiang, Y., Shi, Y., Sui, H., & Zhao, L. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1762262 · Cited by 239

Human secreted tau increases amyloid-beta production

Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230

Reducing acetylated tau is neuroprotective in brain injury

Shin, M.-K., Vázquez-Rosa, E., Koh, Y., Dhar, M., Chaubey, K., Cintrón-Pérez, C. J., Barker, S., Miller, E., Franke, K., Noterman, M. F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.032 · Cited by 226

Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice

Caballero, B., Bourdenx, M., Luengo, E., Diaz, A., Sohn, P. D., Chen, X., Wang, C., Juste, Y. R., Wegmann, S., Patel, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22501-9 · Cited by 223

Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice

Ikegami, S. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00964-7 · Cited by 221

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer’s Disease

Matsuoka, Y., Jouroukhin, Y., Gray, A. J., Ma, L., Hirata‐Fukae, C., Li, H.-F., Feng, L., Lecanu, L., Walker, B. R., Planel, E., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130526 · Cited by 221

miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo

Smith, P. Y., Hernandez-Rapp, J., Jolivette, F., Lecours, C., Bisht, K., Goupil, C., Dorval, V., Parsi, S., Morin, F., Planel, E., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv377 · Cited by 220

Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model

Vulih-Shultzman, I., Pinhasov, A., Mandel, S., Grigoriadis, N., Touloumi, O., Pittel, Z., & Gozes, I. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129551 · Cited by 219

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219

Combination Drug Therapy for the Management of Alzheimer’s Disease

Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease

Collin, L., Bohrmann, B., Göpfert, U., Oroszlan‐Szovik, K., Ozmen, L., & Grüninger, F. (2014) · Brain · doi:10.1093/brain/awu213 · Cited by 208

It’s all about tau

Tapia‐Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W., & Quintanilla, R. A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.005 · Cited by 207

Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation

McEwan, W. A., Falcon, B., Vaysburd, M., Clift, D., Oblak, A. L., Ghetti, B., Goedert, M., & James, L. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607215114 · Cited by 201

The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology

Cotman, C. W., Poon, W. W., Rissman, R. A., & Blurton-Jones, M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.104 · Cited by 199

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193

Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia

Paonessa, F., Evans, L., Solanki, R., Larrieu, D., Wray, S., Hardy, J., Jackson, S. P., & Livesey, F. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.085 · Cited by 189

Silencing of CDK5 Reduces Neurofibrillary Tangles in Transgenic Alzheimer's Mice

Piedrahita, D., Hernández, I., Tobon, A., Fedorov, D., Obara, B., Manjunath, B. S., Boudreau, R. L., Davidson, B. L., LaFerla, F. M., Gallego-Gómez, J. C., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3637-10.2010 · Cited by 188

Curcumin Attenuates Amyloid-β Aggregate Toxicity and Modulates Amyloid-β Aggregation Pathway

Thapa, A., Jett, S. D., & Chi, E. Y. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00214 · Cited by 188

Caspase-2 cleavage of tau reversibly impairs memory

Zhao, X., Kotilinek, L. A., Smith, B., Hlynialuk, C., Zahs, K., Ramsden, M., Cleary, J., & Ashe, K. H. (2016) · Nature Medicine · doi:10.1038/nm.4199 · Cited by 187

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Novak, P., Kovacech, B., Katina, S., Schmidt, R., Scheltens, P., Kontsekova, E., Ropele, S., Fialova, L., Kramberger, M., Paulenka-Ivanovova, N., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00070-2 · Cited by 187

Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody

Albert, M., Mairet‐Coello, G., Danis, C., Lieger, S., Caillierez, R., Carrier, S., Skrobala, E., Landrieu, I., Michel, A., Schmitt, M., et al. (2019) · Brain · doi:10.1093/brain/awz100 · Cited by 186

Anti‐tau antibody reduces insoluble tau and decreases brain atrophy

Yanamandra, K., Jiang, H., Mahan, T. E., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.176 · Cited by 185

PP2A Regulates Tau Phosphorylation Directly and also Indirectly via Activating GSK-3β

Qian, W., Shi, J., Yin, X., Iqbal, K., Grundke-Iqbal, I., Gong, C., & Liu, F. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1317 · Cited by 185

Microdose Lithium Treatment Stabilized Cognitive Impairment in Patients with Alzheimer’s Disease

Nunes, M. A., Viel, T. A., & Buck, H. S. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310010014 · Cited by 183

Nanotechnology-based drug delivery for central nervous system disorders

Nguyen, T. T., Nguyen, T. T. D., Vo, T. K., An, T. N. M., Nguyen, M. K., Toi, V. V., & Vo, G. V. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112117 · Cited by 182

Tauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein

Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178

Hyperdynamic Microtubules, Cognitive Deficits, and Pathology Are Improved in Tau Transgenic Mice with Low Doses of the Microtubule-Stabilizing Agent BMS-241027

Barten, D. M., Fanara, P., Andorfer, C. A., Hoque, N., Wong, P. A., Husted, K. H., Cadelina, G. W., DeCarr, L. B., Yang, L., Liu, V., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0188-12.2012 · Cited by 173

Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

Forlenza, O. V., Radanovic, M., Talib, L. L., & Gattaz, W. F. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2019.76 · Cited by 171

Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer’s Disease

Sonawane, S. K., Ahmad, A., & Chinnathambi, S. (2019) · ACS Omega · doi:10.1021/acsomega.9b01411 · Cited by 170

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

Gu, J., Congdon, E. E., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494922 · Cited by 169

Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo

Morales-Garcia, J. A., Luna‐Medina, R., Alonso‐Gil, S., Sanz-SanCristóbal, M., Palomo, V., Gil, C., Santos, Á., Martı́nez, A., & Pérez‐Castillo, A. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300110c · Cited by 169

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

Hastings, N. B., Wang, X., Song, L., Butts, B. D., Grotz, D., Hargreaves, R., Fred Hess, J., Hong, K.-L. K., Huang, C. R.-R., Hyde, L., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0181-0 · Cited by 164

Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons

Silva, M. C., Nandi, G. A., Tentarelli, S., Gurrell, I. K., Jamier, T., Lucente, D., Dickerson, B. C., Brown, D. G., Brandon, N. J., & Haggarty, S. J. (2020) · Nature Communications · doi:10.1038/s41467-020-16984-1 · Cited by 157

Site-Specific Nitration and Oxidative Dityrosine Bridging of the τ Protein by Peroxynitrite: Implications for Alzheimer's Disease

Reynolds, M. R., Berry, R. W., & Binder, L. I. (2005) · Biochemistry · doi:10.1021/bi047982v · Cited by 154

Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae

Albayram, Ö., Kondo, A., Mannix, R., Smith, C., Tsai, C.-Y., Li, C., Herbert, M. K., Qiu, J., Monuteaux, M. C., Driver, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01068-4 · Cited by 154

Why Pleiotropic Interventions are Needed for Alzheimer's Disease

Frautschy, S. A., & Cole, G. M. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8137-1 · Cited by 152

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Höglinger, G. U., Litvan, I., Mendonça, N., Wang, D., Zheng, H., Rendenbach‐Mueller, B., Lon, H., Jin, Z., Fisseha, N., Budur, K. S., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30489-0 · Cited by 150

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease

Novak, P., Schmidt, R., Kontsekova, E., Kovacech, B., Smolek, T., Katina, S., Fialova, L., Prcina, M., Parrak, V., Dal-Bianco, P., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0436-1 · Cited by 147

Interplay between Cyclin-Dependent Kinase 5 and Glycogen Synthase Kinase 3β Mediated by Neuregulin Signaling Leads to Differential Effects on Tau Phosphorylation and Amyloid Precursor Protein Processing

Wen, Y., Planel, E., Herman, M., Figueroa, H. Y., Wang, L., Liu, L., Lau, L.-F., Yu, W. H., & Duff, K. E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5245-07.2008 · Cited by 145

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

Boxer, A. L., Qureshi, I., Ahlijanian, M. K., Grundman, M., Golbe, L. I., Litvan, I., Honig, L. S., Tuite, P., McFarland, N. R., O’Suilleabhain, P. E., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30139-5 · Cited by 143

Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity

Funk, K. E., Thomas, S. N., Schafer, K. N., Cooper, G. L., Liao, Z., Clark, D. J., Yang, A. J., & Kuret, J. (2014) · Biochemical Journal · doi:10.1042/bj20140372 · Cited by 142

Inhibition of Tau Polymerization by Its Carboxy-Terminal Caspase Cleavage Fragment

Berry, R. W., Abraha, A., Lagalwar, S., LaPointe, N., Gamblin, T. C., Cryns, V. L., & Binder, L. I. (2003) · Biochemistry · doi:10.1021/bi027348m · Cited by 141

Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease

Fortea, J., Vilaplana, E., Alcolea, D. A., Carmona‐Iragui, M., Sánchez‐Saudinós, M., Sala, I., Antón‐Aguirre, S., González‐Ortiz, S., Medrano, S., Pegueroles, J., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24186 · Cited by 140

Cyclin-Dependent Protein Kinase 5 Primes Microtubule-Associated Protein Tau Site-Specifically for Glycogen Synthase Kinase 3β

Li, T., Hawkes, C. A., Qureshi, H. Y., Kar, S., & Paudel, H. K. (2006) · Biochemistry · doi:10.1021/bi051635j · Cited by 139

Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer’s disease

Initiative, A. D. N., Pascoal, T. A., Mathotaarachchi, S. S., Mohades, S. T., Benedet, A. L., Chung, C.-O., Shin, M., Wang, S., Beaudry, T., Kang, M. S., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.37 · Cited by 137

Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau

Courade, J., Angers, R. C., Mairet‐Coello, G., Pacico, N., Tyson, K. L., Lightwood, D. J., Munro, R., McMillan, D., Griffin, R., BAKER, T. S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1911-2 · Cited by 137

Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease

Roberts, M., Sevastou, I., Imaizumi, Y., Mistry, K., Talma, S., Dey, M., Gartlon, J., Ochiai, H., Zhou, Z., Akasofu, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0884-2 · Cited by 135

Overexpressing low‐density lipoprotein receptor reduces tau‐associated neurodegeneration in relation to apoE‐linked mechanisms

Shi, Y., Andhey, P. S., Ising, C., Wang, K., Snipes, L. L., Boyer, K., Lawson, S., Yamada, K., Qin, W., Manis, M., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.05.034 · Cited by 135

The Microtubule-Associated Protein Tau Mediates the Organization of Microtubules and Their Dynamic Exploration of Actin-Rich Lamellipodia and Filopodia of Cortical Growth Cones

Biswas, S., & Kalil, K. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2281-17.2017 · Cited by 133

Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

West, T., Hu, Y., Verghese, P. B., Bateman, R. J., Braunstein, J. B., Fogelman, I., Budur, K., Florian, H., Mendonca, N., & Holtzman, D. M. (2017) · PubMed · doi:10.14283/jpad.2017.36 · Cited by 132

Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model

Zhang, Z.-H., Wu, Q., Zheng, R., Chen, C., Chen, Y., Liu, Q., Hoffmann, P. R., Ni, J., & Song, G.-L. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3229-16.2017 · Cited by 130

Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy

Graham, D. L., Gray, A. J., Joyce, J. A., Yu, D., O’Moore, J., Carlson, G. A., Shearman, M. S., Dellovade, T., & Hering, H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.025 · Cited by 129

Liquid–liquid phase separation of tau: From molecular biophysics to physiology and disease

Rai, S. K., Savastano, A., Singh, P., Mukhopadhyay, S., & Zweckstetter, M. (2021) · Protein Science · doi:10.1002/pro.4093 · Cited by 129

Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation

Gong, C., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9101 · Cited by 128

Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer’s Disease

Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., & Wischik, C. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219352 · Cited by 128

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement

Lee, S.-H., Le Pichon, C. E., Adolfsson, O., Gafner, V., Pihlgren, M., Lin, H., Solanoy, H., Brendza, R., Ngu, H., Foreman, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.099 · Cited by 125

AZD 1080, a novel GSK 3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans

Georgievska, B., Sandin, J., Doherty, J., Mörtberg, A., Neelissen, J. A. M., Andersson, A., Gruber, S. H. M., Nilsson, Y., Schött, P. A., Arvidsson, P. I., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12203 · Cited by 124

AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo

Domise, M., Didier, S., Marinangeli, C., Zhao, H., Chandakkar, P., Buée, L., Viollet, B., Davies, P., Marambaud, P., & Vingtdeux, V. (2016) · Scientific Reports · doi:10.1038/srep26758 · Cited by 124

Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro

Nobuhara, C. K., DeVos, S. L., Commins, C., Wegmann, S., Moore, B. D., Roe, A. D., Costantino, I., Frosch, M. P., Pitstick, R., Carlson, G. A., et al. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.01.022 · Cited by 120

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis

Penke, B., Szűcs, M., & Bogár, F. (2020) · Molecules · doi:10.3390/molecules25071659 · Cited by 119

Propagation of Tau via Extracellular Vesicles

Pérez, M., Avila, J., & Hernández, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00698 · Cited by 118

A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

Morimoto, B. H., Schmechel, D., Hirman, J., Blackwell, A., Keith, J., Gold, M., & on behalf of the AL-108-211 Study Investigators (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000348347 · Cited by 115

AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development

Novák, P., Žilka, N., Žilková, M., Kováčech, B., Škrabana, R., Ondrus, M., Fialová, L., Kontseková, E., Otto, M., & Novák, M. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.45 · Cited by 115

Distinct Therapeutic Mechanisms of Tau Antibodies

Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111

Truncation of Tau selectively facilitates its pathological activities

Gu, J., Xu, W., Jin, N., Li, L., Zhou, Y., Chu, D., Gong, C., Iqbal, K., & Liu, F. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012587 · Cited by 108

Tau Phosphorylation by cdk5 and Fyn in Response to Amyloid Peptide Aβ25–35: Involvement of Lipid Rafts

Hernandez, P., Lee, G., Sjoberg, M., & Maccioni, R. B. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0933 · Cited by 107

Advances and considerations in AD tau-targeted immunotherapy

Bittar, A., Bhatt, N. N., & Kayed, R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 106

Autophagy: A double-edged sword in Alzheimer’s disease

Tung, Y.-T., Wang, B., Hu, M., Hsu, W., Lee, H., Huang, W., & Liao, Y. (2012) · Journal of Biosciences · doi:10.1007/s12038-011-9176-0 · Cited by 105

Crosstalk between Cdk5 and GSK3β: Implications for Alzheimer's Disease

Engmann, O. (2009) · Frontiers in Molecular Neuroscience · doi:10.3389/neuro.02.002.2009 · Cited by 103

ADNP/NAP dramatically increase microtubule end-binding protein–Tau interaction: a novel avenue for protection against tauopathy

Ivashko‐Pachima, Y., Sayas, C. L., Malishkevich, A., & Gozes, I. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.255 · Cited by 102

Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits

Velázquez, R., Ferreira, E., Tran, A., Turner, E. C., Belfiore, R., Branca, C., & Oddo, S. (2018) · Aging Cell · doi:10.1111/acel.12775 · Cited by 102

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2029 · Cited by 100

Action Mechanisms of Curcumin in Alzheimer’s Disease and Its Brain Targeted Delivery

Ege, D. (2021) · Materials · doi:10.3390/ma14123332 · Cited by 97

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies

Dai, C., Chen, X., Kazim, S. F., Liu, F., Gong, C., Grundke, I., & Iqbal, K. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1315-y · Cited by 94

Tau's role in the developing brain: implications for intellectual disability

Sapir, T., Frotscher, M., Levy, T., Mandelkow, E., & Reiner, O. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr603 · Cited by 93

Repositioning Microtubule Stabilizing Drugs for Brain Disorders

Varidaki, A., Hong, Y., & Coffey, E. T. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00226 · Cited by 93

Exploring the bi‐directional relationship between autophagy and Alzheimer’s disease

Kuang, H., Tan, C., Tian, H., Liu, L., Yang, M.-W., Hong, F., & Yang, S. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13216 · Cited by 92

A randomized, single ascending dose study of intravenous BIIB092 in healthy participants

Qureshi, I., Tirucherai, G., Ahlijanian, M. K., Kolaitis, G., Bechtold, C. M., & Grundman, M. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.007 · Cited by 90

Tau immunotherapies: Lessons learned, current status and future considerations

Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90

The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice

Prior, M., Dargusch, R., Ehren, J. L., Chiruta, C., & Schubert, D. A. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt179 · Cited by 89

Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer’s disease mouse and reduces human P301L-tau content at the presymptomatic stage

Shibuya, Y., Niu, Z., Bryleva, E. Y., Harris, B. T., Murphy, S. R., Kheirollah, A., Bowen, Z. D., Chang, C. C. Y., & Chang, T.-Y. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.002 · Cited by 87

DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity

Wu, P.-R., Tsai, P.-I., Chen, G., Chou, H.-J., Huang, Y.-P., Chen, Y. H., Lin, M.-Y., Kimchi, A., Chien, C.-T., & Chen, R.-H. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.2 · Cited by 82

Caspase-Cleaved Tau Impairs Mitochondrial Dynamics in Alzheimer’s Disease

Pérez, M. J., Vergara-Pulgar, K., Jara, C., Cabezas-Opazo, F., & Quintanilla, R. A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0385-x · Cited by 81

12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice

Meco, A. D., Li, J.-G., Blass, B. E., Abou-Gharbia, M. A., Lauretti, E., & Praticò, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.023 · Cited by 80

Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes

Andersson, C. R., Falsig, J., Stavenhagen, J. B., Christensen, S., Kartberg, F., Rosenqvist, N., Finsen, B. R., & Pedersen, J. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-41105-4 · Cited by 79

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls1

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76

A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer’s Disease

Malpas, C. B., Vivash, L. E., Genc, S., Saling, M. M., Desmond, P. M., Steward, C. E., Hicks, R. J., Callahan, J., Brodtmann, A. G., Collins, S. J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160544 · Cited by 75

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer’s Disease

Sun, H., Zhong, Y., Zhu, X., Liao, H., Lee, J., Chen, Y., Ma, L., Ren, J., Zhao, M., Tu, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10690 · Cited by 70

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease

Hu, S., Hu, M., Liu, J., Zhang, B., Zhang, Z., Zhou, F. H., Wang, L., & Dong, J. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s235562 · Cited by 68

B Vitamin Deficiency Promotes Tau Phosphorylation Through Regulation of GSK3β and PP2A

Nicolia, V., Fuso, A., Cavallaro, R. A., Luzio, A. D., & Scarpa, S. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1284 · Cited by 67

Lithium as a Treatment for Alzheimer’s Disease: The Systems Pharmacology Perspective

Hampel, H. J., Lista, S., Mango, D., Nisticò, R., Perry, G. L., Ávila, J., Hernández, F., Geerts, H., Vergallo, A., (APMI), A. P. M. I., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190197 · Cited by 67

Purpurin modulates Tau-derived VQIVYK fibrillization and ameliorates Alzheimer’s disease-like symptoms in animal model

Viswanathan, G. K., Shwartz, D., Losev, Y., Arad, E., Shemesh, C., Pichinuk, E., Engel, H., Raveh, A., Jelinek, R., Cooper, I., et al. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03312-0 · Cited by 67

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66

Characterization of tau binding by gosuranemab

Sopko, R., Golonzhka, O., Arndt, J. W., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Yogapriya, M., Gibbons, G. S., Kim, S., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105120 · Cited by 65

Cis P-tau underlies vascular contribution to cognitive impairment and dementia and can be effectively targeted by immunotherapy in mice

Qiu, C., Albayram, Ö., Kondo, A., Wang, B., Kim, N., Arai, K., Tsai, C.-Y., Bassal, M. A., Herbert, M. K., Washida, K., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7615 · Cited by 65

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

Congdon, E. E., Lin, Y., Rajamohamedsait, H. B., Shamir, D. B., Krishnaswamy, S., Rajamohamedsait, W. J., Rasool, S., González‐Calle, V., Levenga, J., Gu, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0126-z · Cited by 64

Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau

Ait‐Bouziad, N., Chiki, A., Limorenko, G., Xiao, S., Eliezer, D., & Lashuel, H. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.012517 · Cited by 63

Discovery and Structure Activity Relationship of Small Molecule Inhibitors of Toxic β-Amyloid-42 Fibril Formation

Kroth, H., Ansaloni, A., Varisco, Y., Jan, A., Sreenivasachary, N., Rezaei‐Ghaleh, N., Giriens, V., Lohmann, S., López-Deber, M. P., Adolfsson, O., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357665 · Cited by 62

Beneficial network effects of methylene blue in an amnestic model

Riha, P. D., Rojas, J. C., & Gonzalez-Lima, F. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.11.023 · Cited by 60

Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice

Wang, H., Huang, S., Yan, K., Fang, X., Abussaud, A., Martinez, A., Sun, H.-S., & Feng, Z.-P. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.027 · Cited by 59

Nrf2 mediates the expression of BAG3 and autophagy cargo adaptor proteins and tau clearance in an age-dependent manner

Tang, M., Ji, C., Pallo, S. P., Rahman, I., & Johnson, G. V. W. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.001 · Cited by 59

Upregulation of AMPK Ameliorates Alzheimer’s Disease-Like Tau Pathology and Memory Impairment

Wang, L., Li, N., Shi, F.-X., Xu, W., Cao, Y., Lei, Y., Wang, J., Tian, Q., & Zhou, X. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01955-w · Cited by 59

NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse—A microtubule-deficient model of schizophrenia

Wagner, A. M., Pikman, R., Giladi, E., Andrieux, A., & Gozes, I. (2010) · Peptides · doi:10.1016/j.peptides.2010.04.011 · Cited by 58

Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Matsunaga, S., Fujishiro, H., & Takechi, H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190256 · Cited by 57

Open‐Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy

VandeVrede, L. A., Dale, M. L., Fields, S., Frank, M., Hare, E. B., Heuer, H. W., Keith, K., KOESTLER, M. E., Ljubenkov, P. A., McDermott, D., et al. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12940 · Cited by 57

Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy

Congdon, E. E., Chukwu, J. E., Shamir, D. B., Deng, J., Ujla, D., Sait, H. B. R., Neubert, T. A., Kong, X., & Sigurdsson, E. M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.033 · Cited by 56

Tau Immunotherapy

Sigurdsson, E. M. (2016) · Neurodegenerative Diseases · doi:10.1159/000440842 · Cited by 56

Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain

Bajracharya, R., Caruso, A. C., Vella, L. J., & Nisbet, R. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122014 · Cited by 55

The Putative Use of Lithium in Alzheimer's Disease

Morris, G., & Berk, M. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160219113112 · Cited by 53

Highly specific and selective anti‐pS396‐tau antibody C10.2 targets seeding‐competent tau

Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. C. A., Egebjerg, J., Falsig, J., Helboe, L., Jul, P., Kartberg, F., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.005 · Cited by 52

Comorbidity Burden of Dementia: A Hospital-Based Retrospective Study from 2003 to 2012 in Seven Cities in China

Wang, Q., Wang, X., Bu, X., Lian, Y., Xiang, Y., Luo, H.-B., Zou, H., Pu, J., Zhou, Z.-H., Cui, X., et al. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0193-3 · Cited by 49

Tau deletion reduces plaque‐associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease

Peters, F., Salihoglu, H., Pratsch, K., Herzog, É., Pigoni, M., Sgobio, C., Lichtenthaler, S. F., Neumann, U., & Herms, J. W. (2019) · The EMBO Journal · doi:10.15252/embj.2019102345 · Cited by 44

Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease

Timmers, M., Tesseur, I. C., Bogert, J., Zetterberg, H., Blennow, K., Börjesson‐Hanson, A., Baquero, M., Boada, M., RANDOLPH, C. C., Tritsmans, L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.016 · Cited by 43

Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer’s Disease, Lithium, and Autophagy

Damri, O., Shemesh, N., & Agam, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010189 · Cited by 43

Pharmacological Agents Targeting γ-Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer’s Disease Patients: A Systematic Review and Meta-Analysis

Penninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160275 · Cited by 42

Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models

Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42

Evaluation of a PET Radioligand to Image O-GlcNAcase in Brain and Periphery of Rhesus Monkey and Knock-Out Mouse

Paul, S., Haskali, M. B., Liow, J., Zoghbi, S. S., Barth, V., Comly, M., Bond, M. R., Morse, C. L., Gladding, R. L., Frankland, M. P., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213231 · Cited by 41

Microtubule network as a potential candidate for targeting by gold nanoparticle-assisted photothermal therapy

Ghalandari, B., Asadollahi, K., Shakeri‐Zadeh, A., Komeili, A., Riazi, G. H., Kamrava, S. K., & Attaran, N. (2019) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2019.01.012 · Cited by 39

Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies

Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509

Tau-targeting therapies for Alzheimer disease: Current status and future directions

Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371

Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials

Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56

Tau protein binding forms a 1 nm thick layer along protofilaments without affecting the radial elasticity of microtubules

Schaap, I. A. T., Hoffmann, B., Carrasco, C., Merkel, R., & Schmidt, C. F. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.11.010 · Cited by 59

Caspase‐6‐cleaved tau is relevant in Alzheimer's disease and marginal in four‐repeat tauopathies: Diagnostic and therapeutic implications

Theofilas, P., Piergies, A. M. H., Oh, I. M., Lee, Y. B., Li, S. H., Pereira, F. L., Petersen, C., Ehrenberg, A. J., Eser, R. A., Ambrose, A. J., et al. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12819 · Cited by 22

Microtubule-associated protein-τ (MAPT; TAU; FTDP-17)-staining PET reagent for imaging Alzheimer's disease (AD) pathology

(2013) · Science-Business eXchange · doi:10.1038/scibx.2013.1147

Human tau pathology transmits glial tau aggregates in the absence of neuronal tau

Narasimhan, S., Changolkar, L. N., Riddle, D. M., Kats, A. S., Stieber, A., Weitzman, S. A., Zhang, B., Li, Z., Roberson, E. D., Trojanowski, J. Q., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190783 · Cited by 109

Caspase-6-cleaved tau is relevant in Alzheimer’s disease but not in other tauopathies: diagnostic and therapeutic implicationsPreprint

Theofilas, P., Piergies, A. M. H., Li, S. H., et al. (2021) · medRxiv · doi:10.1101/2021.01.28.21250322 · Cited by 1